King Pharmaceuticals

King Pharmaceuticals, Inc.
Company typeSubsidiary
IndustryPharmaceutical company, health care
Founded1994; 30 years ago (1994)
HeadquartersBristol, Tennessee, U.S.
Key people
Brian Markison (CEO)
Joseph Squicciarino (CFO)
Eric J. Bruce (CTO)
ProductsPharmaceuticals
Revenue$1.7 billion USD (2009)[1]
$236 million USD (2009)[1]
$92 million USD (2009)[1]
Number of employees
3,381
ParentPfizer
Websitekingpharm.com

King Pharmaceuticals, Inc. is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company.[1][2] On October 12, 2010, King was acquired by Pfizer for $14.25 per share.[3] King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

King Pharmaceuticals, Inc. was incorporated in the State of Tennessee in 1993. According to the King Pharmaceutcals, Inc. Form 10-K for the year ended December 31, 2007 filed with the U.S. Securities and Exchange Commission, the wholly owned subsidiaries of King Pharmaceuticals, Inc. are Monarch Pharmaceuticals, Inc.; King Pharmaceuticals Research and Development, Inc.; Meridian Medical Technologies, Inc.; Parkedale Pharmaceuticals, Inc.; King Pharmaceuticals Canada Inc.; and Monarch Pharmaceuticals Ireland Limited.[4]

  1. ^ a b c d "Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
  2. ^ "Pharmaceutical Executive - 2006 Top 50 Pharmaceutical Companies" (PDF). Archived from the original (PDF) on 2011-07-11. Retrieved 2007-12-20.
  3. ^ "Pfizer to Buy King Pharmaceuticals for $3.6 Billion". The New York Times. October 12, 2010.
  4. ^ "King Pharmaceuticals, Inc. Form 10-K, Annual report for the fiscal year ended December 31, 2007". SEC Edgar.